FUSION Regimen: Combined Pro re Nata and Fixed Regimen Ranibizumab in Exudative Age-related Macular Degeneration
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the safety and efficacy of a combined
fixed-interval and a pro re nata (PRN) regimens of ranibizumab (FUSION regimen) for the
treatment of exudative age-related macular degeneration (AMD) in patients with good visual
acuity (VA) at baseline. To establish whether similar efficacy to monthly regimens can be
achieved with fewer injections, even in patients with good VA.